Related Experiment Video
Updated: Aug 14, 2026
Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
Published on: August 12, 2015
[Effect of Bcl-2 antisense phosphorothioate oligodeoxynucleotides on bile duct carcinoma cell line QBC939]
Chuang Peng1, Hui-huan Tang, Ping Huang
1Department of General Surgery, Xiangya Hospital, Central South University Changsha, China. tanghuihuan@hotmail.com
Objective:
To investigate the effect of Bcl-2 antisense oligodeoxynucleotides (ASODN) on the cell proliferation and Bcl-2 expression in bile duct carcinoma cell line QBC939.
Methods:
Bcl-2 ASODN and control sequence were transfected into cell line QBC939 by Lipofectamine 2000. The changes of Bcl-2 protein were detected by Western blot. The survival rate and colony formation rate of QBC939 cells incubating with Bcl-2 ASODN were evaluated by trypan blue staining assay and colony forming test.
Results:
The densitometric analysis of Gel-photograph showed that the level of Bcl-2 protein expression in the ASODN transfected group was significantly lower than that in the controls (P < 0.01). Both trypan blue staining assay and colony forming test demonstrated that Bcl-2 ASODN could partially inhibit the growth of QBC939 cells. After incubating with Bcl-2 ASODN, the survival rate and colony formation rate of QBC939 cells were significantly lower than those of the controls (P < 0.05).
Conclusion:
Bcl-2 ASODN inhibits the cell proliferation in bile duct carcinoma cell line QBC939 by blocking the expression of bcl-2 gene.
Insights
Bcl-2 antisense oligodeoxynucleotides (ASODN) significantly reduce Bcl-2 protein expression and inhibit cell proliferation in bile duct carcinoma cells. This study demonstrates ASODN
Area of Science:
- Molecular Biology
- Cancer Research
- Gene Therapy
Context:
- Bile duct carcinoma (BDC) is an aggressive malignancy with limited treatment options.
- The Bcl-2 protein is often overexpressed in BDC, contributing to cell survival and resistance to apoptosis.
- Targeting Bcl-2 offers a potential therapeutic strategy for BDC.
Purpose:
- To evaluate the efficacy of Bcl-2 antisense oligodeoxynucleotides (ASODN) in inhibiting QBC939 bile duct carcinoma cell proliferation.
- To assess the impact of Bcl-2 ASODN on Bcl-2 protein expression in this cell line.
Summary:
- Bcl-2 ASODN transfection significantly downregulated Bcl-2 protein expression in QBC939 cells compared to controls (P < 0.01).
- Both trypan blue staining and colony formation assays confirmed that Bcl-2 ASODN partially inhibited QBC939 cell growth.
- The survival and colony formation rates were significantly reduced in cells treated with Bcl-2 ASODN (P < 0.05).
Impact:
- Bcl-2 ASODN demonstrates potential as a therapeutic agent for bile duct carcinoma by inhibiting cancer cell proliferation.
- This research provides a foundation for further investigation into gene-targeted therapies for BDC.
- Understanding the role of Bcl-2 in BDC can lead to the development of novel treatment strategies.
